Epo Receptors Are Not Detectable in Primary Human Tumor Tissue Samples

por Elliott, Steve, Swift, Susan, Busse, Leigh, Scully, Sheila, Van, Gwyneth, Rossi, John, Johnson, Carol
Publicado 2013

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL...

por Stolina, Marina, Schett, Georg, Dwyer, Denise, Vonderfecht, Steven, Middleton, Scot, Duryea, Diane, Pacheco, Efrain, Van, Gwyneth, Bolon, Brad, Feige, Ulrich, Zack, Debra, Kostenuik, Paul
Publicado 2009

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

por Min, Hosung, Morony, Sean, Sarosi, Ildiko, Dunstan, Colin R., Capparelli, Casey, Scully, Sheila, Van, Gwyneth, Kaufman, Steve, Kostenuik, Paul J., Lacey, David L., Boyle, William J., Simonet, W. Scott
Publicado 2000

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts

por Burgess, Teresa L., Qian, Yi-xin, Kaufman, Stephen, Ring, Brian D., Van, Gwyneth, Capparelli, Charles, Kelley, Michael, Hsu, Hailing, Boyle, William J., Dunstan, Colin R., Hu, Sylvia, Lacey, David L.
Publicado 1999